Markets
Corcept Stock Plunges 9%, Wiping Out $820 Million, After Earnings Report
The drugmaker kept its 2026 revenue forecast, and an FDA decision on relacorilant is due December 17.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Markets
The drugmaker kept its 2026 revenue forecast, and an FDA decision on relacorilant is due December 17.
Earnings
Camtek's CFO blamed parts costs and a stronger shekel for a 51.1% gross margin, while customers book delivery slots through 2027.
Markets
The IT reseller's gross margin slipped to 20.5%, but adjusted earnings rose 20.4% and the quarterly dividend went up.
Earnings
Circle's CEO says the stablecoin issuer aims to compress payments margins, not copy them, as CFO Jeremy Fox-Geen announces his exit.
Earnings
Joel Smejkal credits a structural overhaul, not the cycle, for most of the growth and says Vishay is actively pursuing acquisitions.
Earnings
The company is also "treading water" on a triple-combination drug, and its oral ralinepag supplier carries a compliance flag.
Markets
Shares jumped in Wednesday trading after record third-quarter profit and a first 2027 outlook of 38% to 40% growth.
Earnings
CEO Greg Adelson says nine core wins in the first quarter, more than double last year's four, came from several providers, not one.
Earnings
Mike Doustdar gave analysts "building blocks" for next year as CFO Karsten Munk Knudsen announced his exit after 27 years.
Earnings
Connor Teskey blamed rates, AI worries and policy perception for the gap, as the BEP-BEPC merger vote deadline moved to November 25.
Earnings
Peter Anastasiou, who becomes CEO January 1, 2027, plans multiple deals and a search beyond rare neurological disease.
Earnings
The payments software company's finance chief is departing after three years, and shares were down about 22% to $30.38 in Wednesday trading.